Gilead to expand access to remdesivir, its promising coronavirus treatment
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug SBECD-enabled remdesivir to accelerate its emergency use for multiple
Tag: SBECD
Old but Gold: Applicability of Sulfobutylether Beta Cyclodextrin in SARS-CoV (2002) detection
Coronavirus SARS-CoV caused an outbreak of severe acute respiratory syndrome (SARS) emerged in Guangdong Province, People’s Republic of China in
University Hospitals in US to conduct coronavirus clinical trials
University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised
Hundreds of Virus Patients Allowed to Try Gilead’s Ebola Drug
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
A CycloLab Kft. felveszi a kesztyűt a koronavírus elleni harcban
Az új koronavírus (SARS-CoV-2) okozta megbetegedés (COVID-19) mára több, mint 65 országot és területet érint, majd 90000 regisztrált megbetegedéssel és
Gilead Sciences Initiates Two Phase 3 Studies of Investigational SBECD-enabled Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
Gilead uses SBECD-enabled remdesivir (GS-5734) for treating the first case of the 2019 novel coronavirus in the United States
Gilead Sciences’ SBECD-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,